Last Mile to Microelimination of Hepatitis C Virus Infection Among People Living With Human Immunodeficiency Virus
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Journal Volume
73
Journal Issue
7
Pages
e2172-e2174
Date Issued
2021
Author(s)
Abstract
(See the Major Article by Doyle et al on pages e2164�V71.) Hepatitis C virus (HCV) infection remains a major health problem for people living with human immunodeficiency virus (HIV). It is estimated that 2.3 million people are living with both HCV and HIV worldwide. People living with HIV are 6 times more likely to have HCV infection than those without [1]. Compared with the prevalence rate of HCV coinfection (2.4%) in the general population living with HIV, the rates are higher among bisexual men (4.0%), men who have sex with men (MSM; 6.4%), and people who inject drugs (PWIDs; 82.4%). Coinfection with HIV/HCV is known to accelerate the progression of hepatic fibrosis, which frequently results in liver-related morbidity and mortality, regardless of the use of antiretroviral therapy for HIV [2�V4]. Although the health-related outcome has been improved following treatment-induced HCV clearance, treatment uptake as well as...
SDGs
Publisher
NLM (Medline)
Type
editorial